Insights from Clinical Trials mdpi.com/2073-4468/13/4… Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

⁦Gurbakhash Kaur⁩ is an absolute superstar ! #mmsm ⁦The Tisch Cancer Institute⁩ ⁦Mount Sinai Health System⁩

When will I feel better? Machine learning outperforms conventional regression in predicting organ response in AL Amyloidosis. Excellent work by John Hanna, MD et al. with more to come at IMS and ASH. All collaboration welcome. #mmsm library.ehaweb.org/eha/2025/eha20…

Hot off the presses! #NCCN guidelines v1.2026 now online, and it’s only 2025! Lots of supportive care and treatment updates for patients with #multiplemyeloma nccn.org

Great Blood Cancer Journal RW data from US #MMsm consortium, led by Danai Dima Leyla Shune MD et al! BCMA bsAbs can work in BCMA-exposed. While we await better predictive tools, time & type of prior therapy matters: - ⬆️ PFS if > 9 months since prior BCMA - ⬇️ PFS if prior BCMA was bsAb

Among 25 #mmsm phase 1 trials posted in CT.gov in last 6 months, only 5 have US sites. Most innovation is from China. I just learned of two very promising approaches/drugs that completely abandoned US development. 1/2 clinicaltrials.gov/search?cond=Mu…

The Phase III CARES trial of #anselamimab in #ALAmyloidosis did not meet its primary endpoint, but showed clinically meaningful benefit in a predefined high-risk subgroup. More details to follow at upcoming meetings. BU Amyloidosis Center astrazeneca.com/media-centre/p…

Our review article on the role of XPO1 inhibitor #Selinexor prior to #CART cell therapy in #myeloma Adriana Rossi Tom Martin JCM MDPI #mmsm mdpi.com/2077-0383/14/1…

Peter M. Voorhees, MD, shares key insights from #ASCO25, specifically in the multiple myeloma space. #mmsm | Levine Cancer hubs.li/Q03x7HY70

Excellent guideline on how to think about kidney transplantation in patients with plasma cell disorders. - Aim for good disease control in standard-risk myeloma - Aim for MRD negativity in high-risk myeloma - Avoid IMiDs after transplant if possible - Reduce immunosuppression

Real-World Practice Management of Transplant-Eligible Myeloma sciencedirect.com/science/articl…

As part of our Blood Cancer Awareness Month #KNOWMYELOMA campaign, join us for a 30-minute Q&A with Beth Faiman PhD, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, member of the IMF Nurse Leadership Board. Join us on September 30! facebook.com/events/1333651…

We want to share this important toxicity profile of GPRC5D BisAb- Talquetamab. GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series nature.com/articles/s4140… Full link- rdcu.be/eAazx

congresoslanh.org Estoy alegre de tener la oportunidad de presentar en el Congreso de la SLANH en #Guayaquil sobre la afectación renal en el mieloma. Será una ocasión para compartir ciencia y conectar con colegas de Sudamérica. #mmsm Instituto SLANH Cleveland Clinic

And excellent work by Fred Hutch Cancer Center trainee #swethareddi on accompanying Blood Advances commentary, including table summarizing 3 published analyses of this topic. Bottom line: if you're thinking of PACE or hCVAD as bridging to #MMsm CAR-T, may be time to think of something else!

Excited to share our new paper, out today on Nature Genetics where we use 421 #WGS to reconstruct the evolutionary history of multiple myeloma #mmsm (🔥🔥). Great collaboration with Heidelberg Myeloma Sylvester Comprehensive Cancer Center Mayo Clinic Memorial Sloan Kettering Cancer Center MSK Department of Medicine ⁦.

Timing the relationship of the acquired genetic variants that drive progression of multiple myeloma

Very happy to have the chance to learn from nephrology colleagues from Latin America and to talk a little bit about renal disease in #myeloma and #amyloidosis. If you happen to be at the conference please stop by. #mmsm #onconephrology

A new contribution from MRC myeloma XI showing that with good diagnostic testing functional high risk is very rare ⁦Martin Kaiser⁩